Wer kennt diese Gesellschaft - 500 Beiträge pro Seite
eröffnet am 20.05.09 12:58:46 von
neuester Beitrag 24.05.11 09:44:38 von
neuester Beitrag 24.05.11 09:44:38 von
Beiträge: 14
ID: 1.150.513
ID: 1.150.513
Aufrufe heute: 0
Gesamt: 2.990
Gesamt: 2.990
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 7532 | |
| vor 1 Stunde | 7199 | |
| vor 1 Stunde | 4575 | |
| vor 1 Stunde | 3991 | |
| 02.02.07, 20:48 | 2684 | |
| vor 1 Stunde | 2457 | |
| vor 1 Stunde | 1876 | |
| vor 1 Stunde | 1706 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.735,00 | +1,25 | 201 | |||
| 2. | 7. | 0,3100 | -67,71 | 110 | |||
| 3. | 4. | 0,2110 | +7,11 | 100 | |||
| 4. | 2. | 159,47 | -1,60 | 52 | |||
| 5. | 38. | 2,5545 | +8,70 | 47 | |||
| 6. | 9. | 6,6570 | +0,14 | 41 | |||
| 7. | 12. | 0,1645 | -5,46 | 38 | |||
| 8. | 5. | 4,1525 | -0,48 | 34 |
Feedback
Hier eine E-Mail von Finanznewsletter:
Wer hat eigene Infos dazu?
WKN: A0RBSH. Aktueller Kurs 1,30 Euro
UNSERE PROGNOSE 2 Jahressicht: 5,60 Euro
IN DIESER AKTIE SCHLUMMERT EIN KURSPOTENZIAL VON ÜBER 500% AUF 2-JAHRESSICHT UND WENN SIE WEITERLESEN, WERDEN SIE ERFAHREN, WARUM DIES SO IST...
WIR BEOBACHTEN DIESES PAPIER SEIT LÄNGERER ZEIT UND HEUTE ERGIBT SICH EINE SAGENHAFTE ABSTAUBERCHANCE, denn:
Im Bereich von 1,20 Euro zeichnet sich eine Bodenbildung ab, die IHNEN IN EINER GANZ KURZEN ZEITSPANNE DIE EINMALIGE GELEGENHEIT GIBT, ZU TIEFSTKURSEN, DIE WAHRSCHEINLICH NIEMALS WIEDER GESEHEN WERDEN, MASSIV GROSSE POSITIONEN AUFZUBAUEN UND VOM ZU ERWARTENDEN RALLYESCHUB ÜBERDURCHSCHNITTLICH ZU PROFITIEREN.
Die kurze Konsolidierung ist also ein Geschenk an Sie, Liebe Investoren.
Vertrauen Sie unserer jahrzehntelangen Erfahrung in der Pharmabranche und unserem Gespür für die Trends und die unterbewerteten Aktien, die wir Ihnen mit traumwandlerischer Sicherheit immer wieder aufs neue exklusiv herausfiltern.
Charttechnisch stehen demnach die Ampeln auf grün, und wie sieht es fundamental aus?
GENAUSO!
Global Health Ventures veröffentlichte brandaktuell eine sensationelle Meldung, die nur ein weiteres Mal aufzeigt, dass wir mit unserer extrem positiven Einschätzung dieses Unternehmens völlig richtig liegen.
Die Firma unterzeichnete vor wenigen Stunden einen Vertrag mit der Gesellschaft Vida Pharma aus Montreal, einem Vertragshersteller von pharmazeutischen Medikamenten und Nahrungsergänzungsmitteln. Vida wird Global Health Ventures im Herstellungsprozess von cGMP Material unterstützen. Global Health entwickelt ein neuartiges Medikament für die Verbesserung der sexuellen Potenz bei Männern. Somit ist Vida ein exzellenter Partner für GHLV, vor allem, weil Vida langjährige Erfahrungen in der Produktion von Medikamenten hat.
Wer hat eigene Infos dazu?
WKN: A0RBSH. Aktueller Kurs 1,30 Euro
UNSERE PROGNOSE 2 Jahressicht: 5,60 Euro
IN DIESER AKTIE SCHLUMMERT EIN KURSPOTENZIAL VON ÜBER 500% AUF 2-JAHRESSICHT UND WENN SIE WEITERLESEN, WERDEN SIE ERFAHREN, WARUM DIES SO IST...
WIR BEOBACHTEN DIESES PAPIER SEIT LÄNGERER ZEIT UND HEUTE ERGIBT SICH EINE SAGENHAFTE ABSTAUBERCHANCE, denn:
Im Bereich von 1,20 Euro zeichnet sich eine Bodenbildung ab, die IHNEN IN EINER GANZ KURZEN ZEITSPANNE DIE EINMALIGE GELEGENHEIT GIBT, ZU TIEFSTKURSEN, DIE WAHRSCHEINLICH NIEMALS WIEDER GESEHEN WERDEN, MASSIV GROSSE POSITIONEN AUFZUBAUEN UND VOM ZU ERWARTENDEN RALLYESCHUB ÜBERDURCHSCHNITTLICH ZU PROFITIEREN.
Die kurze Konsolidierung ist also ein Geschenk an Sie, Liebe Investoren.
Vertrauen Sie unserer jahrzehntelangen Erfahrung in der Pharmabranche und unserem Gespür für die Trends und die unterbewerteten Aktien, die wir Ihnen mit traumwandlerischer Sicherheit immer wieder aufs neue exklusiv herausfiltern.
Charttechnisch stehen demnach die Ampeln auf grün, und wie sieht es fundamental aus?
GENAUSO!
Global Health Ventures veröffentlichte brandaktuell eine sensationelle Meldung, die nur ein weiteres Mal aufzeigt, dass wir mit unserer extrem positiven Einschätzung dieses Unternehmens völlig richtig liegen.
Die Firma unterzeichnete vor wenigen Stunden einen Vertrag mit der Gesellschaft Vida Pharma aus Montreal, einem Vertragshersteller von pharmazeutischen Medikamenten und Nahrungsergänzungsmitteln. Vida wird Global Health Ventures im Herstellungsprozess von cGMP Material unterstützen. Global Health entwickelt ein neuartiges Medikament für die Verbesserung der sexuellen Potenz bei Männern. Somit ist Vida ein exzellenter Partner für GHLV, vor allem, weil Vida langjährige Erfahrungen in der Produktion von Medikamenten hat.
Antwort auf Beitrag Nr.: 37.217.866 von geldspender am 20.05.09 12:58:46Einfach mal folgendes durchlesen:
http://www.ghlvs.com/docs/ghlvs%2010-Q.pdf
Wer trotzdem noch kauft, der gehört auf ewig entmündigt!
http://www.ghlvs.com/docs/ghlvs%2010-Q.pdf
Wer trotzdem noch kauft, der gehört auf ewig entmündigt!
Antwort auf Beitrag Nr.: 37.218.020 von Datteljongleur am 20.05.09 13:19:00Liest sich doch gut!
Mein Fazit: strongest buy!
Mein Fazit: strongest buy!
Antwort auf Beitrag Nr.: 37.219.061 von Vermaledeiter am 20.05.09 15:09:36Soll natürlich keine Kaufempfehlung sein!
Ist meine ganz persönliche Meinung!
Ist meine ganz persönliche Meinung!
Antwort auf Beitrag Nr.: 37.219.061 von Vermaledeiter am 20.05.09 15:09:36Liest sich doch gut!
Offensichtlich hast du aber Schwierigkeiten den Inhalt des gelesenen zu bewerten!!
Offensichtlich hast du aber Schwierigkeiten den Inhalt des gelesenen zu bewerten!!
Trading Spotlight
ist doch nur heisse Luft, oder
Aktien zu 0,25 USD ausgegeben, keine Assets, keine Einnahmen, Vermögen der Gesellschaft bei 350.000 mit Kosten von 100.000 pro Jahr. Keine Einnahmen, außer von übertölpelten Aktienkäufern. Warum sollte die Company mit über ein Euro pro Aktie bewertet sein???
Antwort auf Beitrag Nr.: 37.223.992 von traumstrand am 21.05.09 00:05:05Vor allem die Menge der ausgegebenen Aktien ist hoch interessant!!!
Antwort auf Beitrag Nr.: 37.223.992 von traumstrand am 21.05.09 00:05:05http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=65407…
weil so viel Aktien drucken auch Geld kostet
ohne Spass wenn überhaupt wird erst in Jahren ein Profit in Sicht sein. Bis dahin gibts die dann zum Subpennypreis
weil so viel Aktien drucken auch Geld kostet
ohne Spass wenn überhaupt wird erst in Jahren ein Profit in Sicht sein. Bis dahin gibts die dann zum Subpennypreis
Antwort auf Beitrag Nr.: 37.219.267 von Datteljongleur am 20.05.09 15:26:35Wie sollte ich den Inhalt denn bewerten?
Ich kann überhaupt kein Enlisch!
Ich kann überhaupt kein Enlisch!
Antwort auf Beitrag Nr.: 37.245.425 von Vermaledeiter am 25.05.09 15:00:12Dieses Posting (#10) sagt doch schon alles, was man dazu empfehlen kann: FINGER WEG VON SOLCHEN AKTIEN, die in anderen Sprachen und Rechtssystemen handeln. Außer vielleicht den super großen Stocks, wo man auch auf deutsch einige sinnvolle Infos erhält (CocaCola, McDoof o.ä.).
Ich bin des Englischen halbwegs mächtig, habe weiter oben das kurze Fazit berichtet und werde nicht für jeden albernen Pennystock aus Amerika hier noch mehr schreiben.
Dezenter Hinweis: Gerade hier bei WO werden in schöner Regelmäßigkeit US-amerikanische Miniwerte ausgegraben, die selbst in den USA kaum ein Mensch beachtet, und dann wunderbar gepusht und billig eingekaufte Aktien treugläubigen Kleinaktionären zu unerhörten Preisen angedreht...
Ich bin des Englischen halbwegs mächtig, habe weiter oben das kurze Fazit berichtet und werde nicht für jeden albernen Pennystock aus Amerika hier noch mehr schreiben.
Dezenter Hinweis: Gerade hier bei WO werden in schöner Regelmäßigkeit US-amerikanische Miniwerte ausgegraben, die selbst in den USA kaum ein Mensch beachtet, und dann wunderbar gepusht und billig eingekaufte Aktien treugläubigen Kleinaktionären zu unerhörten Preisen angedreht...
Antwort auf Beitrag Nr.: 37.219.267 von Datteljongleur am 20.05.09 15:26:35Scheint doch ein Rohrkrepierer zu sein!
Obwohl der Text dieses Reports so melodisch klang!
Diese Entwicklung hätte ich nie erwartet!
Obwohl der Text dieses Reports so melodisch klang!
Diese Entwicklung hätte ich nie erwartet!
hallo,
dass Global Health so schlecht laufen würde hab ich mir nicht ausgemalt.
Langsam ärgert es micht, dass ich da investiert bin, wenn auch nur ganz wenig.
lang hab ich die nicht mehr
frohe Weihnachten
Trader5000
dass Global Health so schlecht laufen würde hab ich mir nicht ausgemalt.
Langsam ärgert es micht, dass ich da investiert bin, wenn auch nur ganz wenig.
lang hab ich die nicht mehr
frohe Weihnachten
Trader5000
hallo schaut euch dieses aktie mal an , denke das der boden gefunden ist, vieleicht auf die nächste news warten ,oder doch jetzt zuschlagen ?
May 21, 2011 - 1:05 AM EDT
Print Email Article Font Down Font Up Charts
GHLV 0.0519 0.0001
Today 5d 1m 3m 1y 5y 10y
OTC Signal Daily Stock Watch – GHLV
May 21, 2011 (World Stock Wire) --
New York, NY - (WORLD STOCK WIRE) - May 21, 2011 -- OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Today's alerts include: Global Health Ventures, Inc (OTCBB:GHLV) (OTCQB: GHLV)
About Global Health Ventures is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs.
The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In human studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite has completed clinical development in Europe with very good results. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug.
The Company plans to use the same technology to deliver a vast number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress, sleeping disorders, pain killers, anti-allergy medications, heart and lung medication, migraine and addiction replacement therapies.
ABOUT OTC Signal
OTC Signal (www.otcsignal.com) is a stock watch website that provides free daily alerts on stocks. OTC Signal's alerts include news releases or daily e-mails on stocks in all sectors of the market. These include stocks with high or low volume, penny stocks, stocks with technical indicators and much more. OTC Signal tracks stocks that may be moving upwards or downwards. OTC Signal also features companies on its website with company profiles, research reports, analysis, and newsletters.
OTC Signal is an independent electronic publication that provides information on selected publicly traded companies. OTC Signal is not a registered investment advisor or broker-dealer. OTC Signal including affiliates, officers, directors, contractors and employees may buy, sell or hold shares in any company mentioned herein and may profit in the event those shares increase or decrease in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
To join and start receiving our FREE e-mail alerts and newsletter, please visit: http://www.otcsignal.com
Disclaimers-
Release of Liability: Through use of this website viewing or using you agree to hold OTCSignal.com, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities.
The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTC Signal encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTC Signal makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTC Signal has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTC Signal also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in any stock (large-cap, small-cap, or micro-cap security) is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTC Signal makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCSignal.com. OTC Signal owners may or may not hold positions in any of the companies that are profiled.
SAFE HARBOR: The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements. Factors that could cause actual results to differ include but are not limited to; the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, the effectiveness of management's strategies and decisions, general economic and business conditions, new or modified statutory or regulatory requirements and changing price and market conditions. Investing in securities is speculative and carries risk. Past performance does not guarantee future results. No assurance can be given that these are all the factors that could cause actual results to vary materially from the forward-looking statements. The following report is neither an offer to buy or sell securities. Never invest in any stock featured on the OTC Signal Stock Watch website unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list.
OTC Signal
www.otcsignal.com
-
New York, NY -
USA
Phone:
Copyright - World Stock Wire, Inc.
Source: World Stock Wire (May 21, 2011 - 1:05 AM EDT)
News by QuoteMedia
27, 2011 - 8:56 AM EDT
Print Email Article Font Down Font Up Charts
GHLV 0.0519 0.0001
Today 5d 1m 3m 1y 5y 10y
Global Health Ventures to Initiate Discussion With Omnicare on X-Excite vs. Viagra(R) Trials in the United States
Apr. 27, 2011 (GlobeNewswire) --
VANCOUVER, British Columbia, April 27, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company, is pleased to announce that it has started discussions for the clinical trials of X-Excite in North America. The Company has endorsed the work with Omnicare of Philadelphia on the detail of the clinical trials and statistical power required.
The Company has obtained valuable information on the European clinical trials for X-Excite and will begin designing a successful trial in the United States. The work will be conducted by Omnicare, a well-respected and internationally known contract research organization (CRO). Omnicare is a U.S. based CRO with its head office in Philadelphia, PA including twenty other offices throughout the world.
"We are pleased for the advances we have been making on the development of X-Excite by engaging highly expert firms to assist us on our business development", said Dr. Hassan Salari, Global Health President & CEO.
About Sublingual Technology
The Company's sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly and efficiently. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver breakdown. It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection. The technology is tested against 40 major drugs and all can benefit from it.
About Global Health Ventures (OTCBB:GHLV) is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In human studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite has completed clinical development in Europe with very good results. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress, sleeping disorders, pain killers, anti-allergy medications, heart and lung medication, migraine and addiction replacement therapies.
Notice Regarding Forward Looking Statements -This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.
CONTACT: For Investor Relations Contact:
Mrs. Kelly Black
Premier Media Service Inc.
(480) 649-8224
kblack@premiermediaservice.com
Source: Globe Newswire (April 27, 2011 - 8:56 AM EDT)
News by QuoteMedia
April 12, 2011 - 8:56 AM EDT
Print Email Article Font Down Font Up Charts
GHLV 0.0519 0.0001
Today 5d 1m 3m 1y 5y 10y
Global Health Ventures Completes X-Excite Formulation for North American Clinical Trials
Apr. 12, 2011 (GlobeNewswire) --
VANCOUVER, British Columbia, April 12, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV) a specialty pharmaceutical company is pleased to announce that has completed the final formulation of its lead therapeutics drug, X-Excite for the upcoming clinical trials in the United States. Results of the interim clinical trials in Europe showed X-Excite to appear in the blood rapidly and stay for longer time than the brand, Viagra®. It is believed the longer presence of the drug in the blood may contribute to both buccal (sublingual) absorption and the gastric absorption. For North American trials, the Company has modified the formulation slightly to give the maximal buccal absorption.
"We are very pleased with the results of our European clinical trials. Now we have fine tuned our formulation for the North American clinical trials. With the final formulation, we can now contract out the GMP manufacturing of the drug to a qualified Contract Manufacturing Organization (CMO) and initiate the clinical trials soon after having the drug on hand," said Dr. Hassan Salari, President & CEO of Global Health.
About Sublingual Technology The Company's sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly and efficiently. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver break down. It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection. The technology is tested against 40 major drugs and all can benefit from it.
About Global Health Ventures (OTCBB:GHLV) is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite is presently in clinical development in Europe. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress, sleeping disorders, pain killers, anti-allergy medications, heart and lung medication, migraine and addiction replacement therapies. For more information visit http://www.globalhealth3000.com/
http://premierstocks.tv/index.php?option=com_content&view=se…
Notice Regarding Forward Looking Statements -This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.
CONTACT: For Investor Relations Contact:
Mrs. Kelly Black
Premier Media Service Inc
(480) 649-8224 or 866 216-8814
kblack@premiermediaservice.com
Source: Globe Newswire (April 12, 2011 - 8:56 AM EDT)
News by QuoteMedia
Global Health Ventures Announces Interim Data From the European Clinical Trails of X-Excite vs. Viagra
Mar. 30, 2011 (GlobeNewswire) --
VANCOUVER, British Columbia, March 30, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company, is pleased to announce the interim results of the clinical trials conducted in Europe under the EMEA guideline protocols for its lead therapeutic drug, X-Excite.
Data analysis from a small number of patients showed the drug to meet the three Pharmacokinetics (PK) end points. Blood analysis of the patients receiving X-Excite showed the drug to appear in the blood 173% faster than Pfizer Viagra®. By 10 minutes about one quarter of peak concentration (T max Value) apeared in the blood. Further, X-Excite (blood concentration, C max) never exceeded the C max of Viagra®, a good sign for drug's acceptability as biosimilar. Additionally the T max was lower (about 15%), and better (wider) spread, a possible sign of less side effects. Finally it appeared that X-Excite remains in the blood slightly longer than Viagra®, possibly due to some gastric absorption, thus may provide a longer performance. Although these are the results of a small number of patients, it indicates a highly positive trend and it is meeting our expectations.
Additional studies are underway and further data will be released upon their availability. In this study we compared the blood profile of X-Excite with Pfizer's Viagra® in a neck to neck study. In the trials, an open label PK profiling of both drugs were conducted in 24 patients of which 12 received Viagra® and 12 received X-Excite. X-Excite is a sublingual formulation of sildenafil citrate. Sildenafil citrate is used to make one of Pfizer Incorporated's largest sellers Viagra®.
"We are very pleased with the interim data thus far obtained and looking forward to get additional data, and full blood profiling from our partners in Europe. The data obtained from this small study is highly encouraging and merits the next study to be conducted under FDA guidelines in the United States," said Dr. Hassan Salari, Global Health President & CEO.
About Sublingual Technology
The Company's sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly and efficiently. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver breakdown. It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection. The technology is tested against 40 major drugs and all can benefit from it.
About Global Health Ventures (OTCBB:GHLV)
Global Health Ventures is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite is presently in clinical development in Europe. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress, sleeping disorders, pain killers, anti-allergy medications, heart and lung medication, migraine and addiction replacement therapies.
Notice Regarding Forward Looking Statements -This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.
CONTACT: For Investor Relations Contact:
Mrs. Kelly Black
Premier Media Service Inc.
1 (480) 649-8224
kblack@premiermediaservice.com
Source: Globe Newswire (March 30, 2011 - 9:12 AM EDT)
News by QuoteMedia
Untersuchung des Anlegerverhaltens von Privatanlegern.
Untersuchung des Anlegerverhaltens von Privatanlegern.
Marcel Czink
kaufen
May 21, 2011 - 1:05 AM EDT
Print Email Article Font Down Font Up Charts
GHLV 0.0519 0.0001
Today 5d 1m 3m 1y 5y 10y
OTC Signal Daily Stock Watch – GHLV
May 21, 2011 (World Stock Wire) --
New York, NY - (WORLD STOCK WIRE) - May 21, 2011 -- OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Today's alerts include: Global Health Ventures, Inc (OTCBB:GHLV) (OTCQB: GHLV)
About Global Health Ventures is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs.
The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In human studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite has completed clinical development in Europe with very good results. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug.
The Company plans to use the same technology to deliver a vast number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress, sleeping disorders, pain killers, anti-allergy medications, heart and lung medication, migraine and addiction replacement therapies.
ABOUT OTC Signal
OTC Signal (www.otcsignal.com) is a stock watch website that provides free daily alerts on stocks. OTC Signal's alerts include news releases or daily e-mails on stocks in all sectors of the market. These include stocks with high or low volume, penny stocks, stocks with technical indicators and much more. OTC Signal tracks stocks that may be moving upwards or downwards. OTC Signal also features companies on its website with company profiles, research reports, analysis, and newsletters.
OTC Signal is an independent electronic publication that provides information on selected publicly traded companies. OTC Signal is not a registered investment advisor or broker-dealer. OTC Signal including affiliates, officers, directors, contractors and employees may buy, sell or hold shares in any company mentioned herein and may profit in the event those shares increase or decrease in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
To join and start receiving our FREE e-mail alerts and newsletter, please visit: http://www.otcsignal.com
Disclaimers-
Release of Liability: Through use of this website viewing or using you agree to hold OTCSignal.com, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities.
The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTC Signal encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTC Signal makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTC Signal has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTC Signal also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in any stock (large-cap, small-cap, or micro-cap security) is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTC Signal makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCSignal.com. OTC Signal owners may or may not hold positions in any of the companies that are profiled.
SAFE HARBOR: The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements. Factors that could cause actual results to differ include but are not limited to; the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, the effectiveness of management's strategies and decisions, general economic and business conditions, new or modified statutory or regulatory requirements and changing price and market conditions. Investing in securities is speculative and carries risk. Past performance does not guarantee future results. No assurance can be given that these are all the factors that could cause actual results to vary materially from the forward-looking statements. The following report is neither an offer to buy or sell securities. Never invest in any stock featured on the OTC Signal Stock Watch website unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list.
OTC Signal
www.otcsignal.com
-
New York, NY -
USA
Phone:
Copyright - World Stock Wire, Inc.
Source: World Stock Wire (May 21, 2011 - 1:05 AM EDT)
News by QuoteMedia
27, 2011 - 8:56 AM EDT
Print Email Article Font Down Font Up Charts
GHLV 0.0519 0.0001
Today 5d 1m 3m 1y 5y 10y
Global Health Ventures to Initiate Discussion With Omnicare on X-Excite vs. Viagra(R) Trials in the United States
Apr. 27, 2011 (GlobeNewswire) --
VANCOUVER, British Columbia, April 27, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company, is pleased to announce that it has started discussions for the clinical trials of X-Excite in North America. The Company has endorsed the work with Omnicare of Philadelphia on the detail of the clinical trials and statistical power required.
The Company has obtained valuable information on the European clinical trials for X-Excite and will begin designing a successful trial in the United States. The work will be conducted by Omnicare, a well-respected and internationally known contract research organization (CRO). Omnicare is a U.S. based CRO with its head office in Philadelphia, PA including twenty other offices throughout the world.
"We are pleased for the advances we have been making on the development of X-Excite by engaging highly expert firms to assist us on our business development", said Dr. Hassan Salari, Global Health President & CEO.
About Sublingual Technology
The Company's sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly and efficiently. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver breakdown. It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection. The technology is tested against 40 major drugs and all can benefit from it.
About Global Health Ventures (OTCBB:GHLV) is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In human studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite has completed clinical development in Europe with very good results. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress, sleeping disorders, pain killers, anti-allergy medications, heart and lung medication, migraine and addiction replacement therapies.
Notice Regarding Forward Looking Statements -This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.
CONTACT: For Investor Relations Contact:
Mrs. Kelly Black
Premier Media Service Inc.
(480) 649-8224
kblack@premiermediaservice.com
Source: Globe Newswire (April 27, 2011 - 8:56 AM EDT)
News by QuoteMedia
April 12, 2011 - 8:56 AM EDT
Print Email Article Font Down Font Up Charts
GHLV 0.0519 0.0001
Today 5d 1m 3m 1y 5y 10y
Global Health Ventures Completes X-Excite Formulation for North American Clinical Trials
Apr. 12, 2011 (GlobeNewswire) --
VANCOUVER, British Columbia, April 12, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV) a specialty pharmaceutical company is pleased to announce that has completed the final formulation of its lead therapeutics drug, X-Excite for the upcoming clinical trials in the United States. Results of the interim clinical trials in Europe showed X-Excite to appear in the blood rapidly and stay for longer time than the brand, Viagra®. It is believed the longer presence of the drug in the blood may contribute to both buccal (sublingual) absorption and the gastric absorption. For North American trials, the Company has modified the formulation slightly to give the maximal buccal absorption.
"We are very pleased with the results of our European clinical trials. Now we have fine tuned our formulation for the North American clinical trials. With the final formulation, we can now contract out the GMP manufacturing of the drug to a qualified Contract Manufacturing Organization (CMO) and initiate the clinical trials soon after having the drug on hand," said Dr. Hassan Salari, President & CEO of Global Health.
About Sublingual Technology The Company's sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly and efficiently. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver break down. It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection. The technology is tested against 40 major drugs and all can benefit from it.
About Global Health Ventures (OTCBB:GHLV) is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite is presently in clinical development in Europe. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress, sleeping disorders, pain killers, anti-allergy medications, heart and lung medication, migraine and addiction replacement therapies. For more information visit http://www.globalhealth3000.com/
http://premierstocks.tv/index.php?option=com_content&view=se…
Notice Regarding Forward Looking Statements -This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.
CONTACT: For Investor Relations Contact:
Mrs. Kelly Black
Premier Media Service Inc
(480) 649-8224 or 866 216-8814
kblack@premiermediaservice.com
Source: Globe Newswire (April 12, 2011 - 8:56 AM EDT)
News by QuoteMedia
Global Health Ventures Announces Interim Data From the European Clinical Trails of X-Excite vs. Viagra
Mar. 30, 2011 (GlobeNewswire) --
VANCOUVER, British Columbia, March 30, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company, is pleased to announce the interim results of the clinical trials conducted in Europe under the EMEA guideline protocols for its lead therapeutic drug, X-Excite.
Data analysis from a small number of patients showed the drug to meet the three Pharmacokinetics (PK) end points. Blood analysis of the patients receiving X-Excite showed the drug to appear in the blood 173% faster than Pfizer Viagra®. By 10 minutes about one quarter of peak concentration (T max Value) apeared in the blood. Further, X-Excite (blood concentration, C max) never exceeded the C max of Viagra®, a good sign for drug's acceptability as biosimilar. Additionally the T max was lower (about 15%), and better (wider) spread, a possible sign of less side effects. Finally it appeared that X-Excite remains in the blood slightly longer than Viagra®, possibly due to some gastric absorption, thus may provide a longer performance. Although these are the results of a small number of patients, it indicates a highly positive trend and it is meeting our expectations.
Additional studies are underway and further data will be released upon their availability. In this study we compared the blood profile of X-Excite with Pfizer's Viagra® in a neck to neck study. In the trials, an open label PK profiling of both drugs were conducted in 24 patients of which 12 received Viagra® and 12 received X-Excite. X-Excite is a sublingual formulation of sildenafil citrate. Sildenafil citrate is used to make one of Pfizer Incorporated's largest sellers Viagra®.
"We are very pleased with the interim data thus far obtained and looking forward to get additional data, and full blood profiling from our partners in Europe. The data obtained from this small study is highly encouraging and merits the next study to be conducted under FDA guidelines in the United States," said Dr. Hassan Salari, Global Health President & CEO.
About Sublingual Technology
The Company's sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly and efficiently. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver breakdown. It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection. The technology is tested against 40 major drugs and all can benefit from it.
About Global Health Ventures (OTCBB:GHLV)
Global Health Ventures is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite is presently in clinical development in Europe. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress, sleeping disorders, pain killers, anti-allergy medications, heart and lung medication, migraine and addiction replacement therapies.
Notice Regarding Forward Looking Statements -This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.
CONTACT: For Investor Relations Contact:
Mrs. Kelly Black
Premier Media Service Inc.
1 (480) 649-8224
kblack@premiermediaservice.com
Source: Globe Newswire (March 30, 2011 - 9:12 AM EDT)
News by QuoteMedia
Untersuchung des Anlegerverhaltens von Privatanlegern.
Untersuchung des Anlegerverhaltens von Privatanlegern.
Marcel Czink
kaufen
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 201 | ||
| 110 | ||
| 100 | ||
| 52 | ||
| 47 | ||
| 41 | ||
| 38 | ||
| 34 | ||
| 33 | ||
| 30 |
| Wertpapier | Beiträge | |
|---|---|---|
| 30 | ||
| 25 | ||
| 25 | ||
| 24 | ||
| 16 | ||
| 15 | ||
| 14 | ||
| 13 | ||
| 11 | ||
| 10 |
